The estimated Net Worth of Capital Management Lp Rosen... is at least $46.8 million dollars as of 9 December 2022. Capital Rosen owns over 14,825 units of Mereo BioPharma plc stock worth over $8,188,510 and over the last 3 years Capital sold MREO stock worth over $38,657,000.
Capital has made over 12 trades of the Mereo BioPharma plc stock since 2021, according to the Form 4 filled with the SEC. Most recently Capital sold 29,000 units of MREO stock worth $38,657,000 on 30 December 2022.
The largest trade Capital's ever made was buying 1,678,954 units of Mereo BioPharma plc stock on 10 August 2022 worth over $16,907,067. On average, Capital trades about 308,414 units every 26 days since 2021. As of 9 December 2022 Capital still owns at least 1,757,191 units of Mereo BioPharma plc stock.
You can see the complete history of Capital Rosen stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is 155 EAST 44TH ST, SUITE 1630155 EAST 44TH ST, SUITE 1630, , NEW YORKNEW YORK, NYNY, 1001710017.
Over the last few years, insiders at Mereo BioPharma plc have traded over $974,160 worth of Mereo BioPharma plc stock. The most active insiders traders include Capital Management Lp Rosen..., Deepika Pakianathan et Denise Scots Knight. On average, Mereo BioPharma plc executives and independent directors trade stock every 8 days with the average trade being worth of $447,435. The most recent stock trade was executed by Deepika Pakianathan on 22 August 2024, trading 105,244 units of MREO stock currently worth $151,551.
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.
Mereo BioPharma plc executives and other stock owners filed with the SEC include: